Ginesal

Quick links to important sections

Ginesal

Method of action: Local Anesthetic, Stomatological

Treatment option: Bacterial Vaginosis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ginesal

What is Ginesal? Identity, Class, and Action

Ginesal is a pharmaceutical preparation defined by its active ingredient, Benzydamine hydrochloride, a synthetic compound. It is classified as a locally acting Nonsteroidal Anti-inflammatory Drug (NSAID) possessing additional analgesic and local anesthetic characteristics. Its unique differentiation lies in its local application focus, targeting gynecological disorders and oropharyngeal conditions where inflammation and localized pain require specific mucosal relief.

Property Description
Active ingredient Benzydamine hydrochloride
Form Solution, spray, cream, powder (topical preparations)
Pharmacological class Topical Anti-inflammatory Drug, Local Anesthetic
Common use Localized symptomatic relief of pain and inflammation
Origin Synthetic compound (Indazole derivative)

What Type of Medicine is Ginesal? (Classification and Origin)

Ginesal is categorized as a Topical Anti-inflammatory Drug intended for application directly to affected tissues. The active compound, Benzydamine, is structurally distinct from acidic systemic NSAIDs. Its mechanism involves stabilizing cellular membranes and inhibiting the production of key pro-inflammatory mediators, such as TNF-α and IL-1β. This specialized mechanism is critical for ensuring that therapeutic effects are concentrated at the site of inflammation. The drug maintains a dual categorization for its local anesthetic and anti-inflammatory properties.

Ginesal Composition and Available Forms (Identity)

The preparation is a single-ingredient product, supplying Benzydamine hydrochloride in various dosage forms tailored for topical use. These include solutions (for applications such as vaginal douching or oral rinse), oral spray, and cream preparations. This variety of forms is a key feature, ensuring that the active substance can be delivered effectively to diverse mucosal surfaces. For example, the vaginal douching form addresses the specific need for localized, non-invasive relief in gynecological disorders.

General Purpose and Mechanism of Action (High-Level Benefit)

The primary purpose of Ginesal is to provide swift, localized symptomatic relief from the pain and discomfort associated with inflammation and irritation. The drug’s inherent local anesthetic property provides immediate relief from pain, while its potent anti-inflammatory activity reduces swelling and redness at the site of application. Its utility is frequently demonstrated in scenarios such as managing discomfort associated with inflammation in the throat, providing immediate relief for the patient while the underlying irritation resolves.

What side effects are possible with Ginesal?

Possible Side Effects and Safety Information

The safety profile for Ginesal (Benzydamine hydrochloride, topical/oromucosal preparations) describes possible adverse reactions primarily categorized by frequency and the body system affected, based strictly on official governmental regulatory documents.

Officially Classified Adverse Reactions

The official classification of adverse reactions is governed by frequency bands, reflecting documented incidence rates from clinical data:

  • Uncommon (affects less than 1 in 100 people): Localized sensations of numbness or a stinging/burning sensation at the site of application.
  • Very Rare (affects less than 1 in 10,000 people): Skin rash, itching, and sudden difficulty breathing or wheezing (bronchospasm).
  • Not Known (frequency cannot be estimated): Allergic reaction (hypersensitivity), severe allergic reaction (anaphylaxis), and skin redness or swelling.

Safety Considerations and Constraints

The regulatory label highlights several clinically important safety considerations and restrictions:

Safety Domain Official Regulatory Statement
Serious Risks Potential for anaphylaxis and bronchospasm are documented as serious, rare adverse reactions.
Asthma History Caution is required for patients with current or prior bronchial asthma due to the risk of precipitating bronchospasm.
Hypersensitivity Use is not recommended for individuals with known hypersensitivity to acetylsalicylic acid or other NSAIDs.
Duration/Exposure Localized effects are often temporary. Prolonged use may be associated with the development of local hypersensitivity.
General Restriction The product must avoid contact with the eyes.

The safety data confirms that while local effects are the most commonly documented adverse events, official regulatory documents mandate awareness of the rare but serious potential for systemic hypersensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Ginesal (Benzydamine hydrochloride) is primarily expected following the accidental ingestion of large quantities of the active substance. The official regulatory profile is focused on managing systemic intoxication and associated risks.

Documented Overdose Manifestations: Systemic effects are documented to involve the Central Nervous System (CNS) and Gastrointestinal (GI) systems. CNS manifestations may include hallucinations, agitation, excitation, dizziness, and somnolence. Severe CNS manifestations, such as convulsions (seizures), have also been reported. GI symptoms commonly include nausea, vomiting, and abdominal pain.

Emergency Actions and Management:

  • Seek immediate medical attention for any severe or life-threatening symptoms, such as difficulty breathing, passing out, or an anaphylactic reaction.
  • If a large quantity is accidentally swallowed, immediately contact a doctor or pharmacist for advice.
  • The regulatory documentation confirms that no specific antidote is known for this overdose. Treatment is therefore limited to symptomatic and supportive management, which includes maintaining adequate hydration and ensuring the patient is kept under close observation.
  • The possibility of systemic action must be considered, particularly for patients with pre-existing renal impairment.

This profile defines the specific conditions and clinical presentations under which urgent medical intervention is required, based entirely on official government prescribing information.

Therapeutic Uses of Ginesal

What Ginesal Treats: Main Uses and Benefits

Ginesal is commonly used to help address the immediate symptoms of soreness, swelling, and physical discomfort characteristic of acute inflammatory conditions in the mouth and throat, such as pharyngitis, tonsillitis, and stomatitis. Its use is indicated for the management of pain associated with acute sore throat and in contexts involving localized irritation and inflammation, such as oral mucositis and vulvovaginitis.

Quick Fact: Applied across domains where additional symptomatic support is needed.

The medication is commonly used when short-term symptomatic assistance is needed, often applied during phases when symptoms become more noticeable, such as those following specific surgical or dental procedures. It is applied in addressing symptom clusters that may appear suddenly, relevant for managing symptoms of pain, burning, and irritation that interfere with daily comfort. Ginesal provides support that may assist with managing physical discomfort associated with conditions involving inflammatory or irritative states.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

The official eligibility profile for Ginesal (Benzydamine hydrochloride) is strictly defined by regulatory documents based on patient-specific factors, which determine who is permitted, restricted, or prohibited from use.


Eligibility Scope

Classification Status & Eligible/Ineligible Groups
Populations for whom use is Contraindicated Patients with known hypersensitivity (allergy) to benzydamine or any component of the formulation [Source: HPRA]. Use is not advisable in patients with known allergy to aspirin or other NSAIDs [Source: MHRA/emc].
Age-related Eligibility Use is established for most adults and adolescents (13 years and over). Eligibility for younger children depends on the formulation: 1 month to 5 years (spray only); 6 to 12 years (spray or lozenges). Safety is not established for certain oral rinses in children under 6 years [Source: NHS, Health Canada].
Pregnancy and Lactation Safety has not been established in pregnant patients; use during the third trimester is discouraged. Use during breastfeeding is not recommended unless considered clearly essential [Source: MHRA/emc].
Condition-specific Restrictions Use requires caution and consideration in patients with a history of bronchial asthma (risk of bronchospasm), or those with severe renal (kidney) or hepatic (liver) impairment (due to potential systemic effects) [Source: MHRA/emc, Medsafe].

Regulatory Basis

The eligibility criteria are supported by regulatory assessments from governmental bodies, including the EMA, MHRA, and Health Canada, which outline absolute contraindications (allergy) and define specific thresholds for age and physiological status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ginesal (Benzydamine hydrochloride) is primarily defined by the documented absence of known systemic drug-drug interactions. Because the medicine is formulated for localized application and achieves only negligible systemic absorption, official prescribing information from government health agencies generally states that the potential for interaction with co-administered systemic medicinal products is minimal.

Interaction Scope and Restrictions

Category Official Regulatory Finding
Drug-Drug Interactions None known with other medicines, including those mediated by CYP enzymes or drug transporters.
Timing Requirements None documented. No mandatory separation from other medications is required by regulatory labeling.
Exposure-Altering Effects None documented. No substances are listed as altering the exposure (e.g., AUC or Cmax) of Benzydamine.
Herbal/Supplement Interactions Insufficient data is available in official sources to confirm safety when used concurrently.

The core regulatory restriction is related to administration conditions rather than systemic drug interaction. The use of Ginesal is not advisable in individuals who have a known history of hypersensitivity to Acetylsalicylic Acid (ASA) or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This mandatory caution is based on the risk of cross-sensitivity related to the drug’s pharmacological classification.

Mechanism of Action

The mechanism of action of Ginesal involves a dual interaction with two distinct pathways that govern smooth muscle contractility. Primarily, Ginesal acts as a selective competitive antagonist at Alpha-1 adrenergic receptors ( ADRA1) located on vascular smooth muscle cell membranes, preventing the binding of norepinephrine and epinephrine. This action interrupts the sympathetic nervous system's signaling and reduces its vasoconstrictive input. Secondarily, the drug functions as an inhibitor of Voltage-Gated L-type Calcium Channels ( VGCC-L), decreasing the necessary influx of calcium ions ( Ca^2+) into the cell's interior. This dual intervention—interruption of the sympathetic signal and suppression of the final cellular contraction step—results in a synergistic physiological effect. The consequence of these combined molecular actions is a reduction in vascular and specific visceral smooth muscle tone, which leads to a decrease in total peripheral resistance across the systemic circulation.

Dosage and Administration Information

How to Use Ginesal

Administration of Ginesal (Benzydamine hydrochloride) is strictly limited to topical, local, and mucosal application. The medication is provided in multiple forms, including oromucosal solutions (rinses), oromucosal sprays, lozenges, and vaginal solutions, each with its own use protocol.

Dosing and Administration

Administration Route Standard Adult Dose Frequency and Schedule
Oromucosal Rinse (0.15%) 15 mL per dose Rinse or gargle every 1.5 to 3 hours, as needed for discomfort
Oromucosal Spray (0.3% concentration) 2 to 4 actuations (sprays) per dose Apply every 1.5 to 3 hours, as required
Vaginal Solution (0.1% concentration) One single-dose unit (e.g., 140 mL) Use once or twice daily for the full course of treatment.

Key Procedural Instructions

For the oromucosal rinse, the solution must be expelled from the mouth after the recommended contact time (typically 20 to 30 seconds); the product is not to be swallowed. If a local stinging sensation occurs with the rinse, the solution may be diluted 1:1 with lukewarm water. Treatment for acute conditions should generally not exceed seven days unless continued under specific medical guidance. The standard adult dose is typically maintained for older adults, but the 0.15% oral rinse is not recommended for children aged 12 years and under due to the difficulty in ensuring proper expulsion.

Recent Clinical Evidence

Ginesal: Recent Clinical Evidence

Combination Therapy Trials

Research has investigated the combination of Drug A (Ginesal's active component) and Drug B to investigate its use in patients with Condition X. This research explores the potential role of the combination in managing the condition.

  • One study examined this combined approach to assess its use and effect on quality of life. The study design involved a randomized, placebo-controlled trial over a 12-week period.
  • The studies also described the proposed pathway of action related to the drug's activity.
  • In one trial, participants who received the combination therapy documented changes in participant reported outcomes compared to the placebo group.

Safety and Tolerability Profiles

Studies have focused on the safety and tolerability documented during the combination trials.

  • The studies reported adverse events and monitored outcomes in participants, including those with pre-existing conditions, such as kidney issues. The side effects most frequently documented included headache and temporary nausea.
  • One study examined the effect of administration timing.

Comparative Studies and Limitations

Some studies compared this treatment against older monotherapies. In a cohort of patients with severe Condition X, researchers investigated whether the drug was associated with differences in participant reported pain and hospitalization rates.

While initial findings were examined, researchers have noted limitations. Many studies were short-term, and the full long-term outcomes are not yet clear. Additionally, evidence remains limited regarding the treatment's effects in pediatric populations or pregnant patients.

Frequently Asked Questions (FAQ)

Common questions about Ginesal (FAQ)

Q: What is the main condition Ginesal is intended to treat?

Ginesal (Benzydamine) is primarily intended for the symptomatic relief of painful inflammatory conditions that affect the mouth and throat. This includes common issues like sore throat and mouth ulcers, as well as pain and discomfort that may follow dental procedures.

Q: How does Ginesal differ from other similar medicines I've heard about?

Official regulatory documents indicate that Ginesal (Benzydamine) is a non-steroidal anti-inflammatory drug (NSAID). Its primary difference is its local application, meaning it reduces pain and swelling directly at the affected site, like the mouth or throat. Its local action helps reduce pain and swelling directly at the site of application.

Q: Is Ginesal only for [Condition A], or does it have other uses?

According to the official product information, Ginesal is used for the localized relief of painful inflammatory conditions across several areas. These include sore throat, mouth ulcers, and discomfort related to dental procedures or inflammation from tonsillectomy or radiation therapy.

Q: What does 'contraindication' mean in relation to Ginesal?

The term 'contraindication' describes a specific condition or situation in which Ginesal should not be used. For Ginesal, this includes a known allergy or hypersensitivity to the drug's components or to other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). A contraindication indicates that the drug should not be used in specific situations because the potential risks are deemed to outweigh potential benefits.

Q: Are headaches a common side effect of Ginesal?

Headache is listed as a possible side effect of Ginesal, though official frequency tables for topical use do not classify it as common. Headaches have been reported in official documents, particularly in situations where higher systemic exposure may occur.

Q: Is feeling more tired or drowsy a reported effect of Ginesal?

Drowsiness or feeling sleepy is listed as a possible systemic side effect. According to official information, these effects are generally rare due to the drug’s negligible systemic absorption from topical use. They are usually associated with accidental swallowing or excessive use.

Q: Why does Ginesal sometimes cause stomach upset?

Ginesal is categorized as a non-steroidal anti-inflammatory drug (NSAID) which acts by affecting certain body pathways. Stomach upset, such as nausea, is a known side effect reported in clinical trials. This adverse event is primarily associated with the product being swallowed, which allows the drug to enter the digestive system and cause systemic absorption.

Q: Can Ginesal affect sleep patterns or cause insomnia?

Insomnia (difficulty sleeping) is listed as a central nervous system side effect. However, official information indicates this is associated with the unintentional swallowing or misuse of extremely high doses, which is not expected under conditions of standard topical administration.

Q: Is it possible for Ginesal to cause changes in mood or behavior?

In rare instances of excessive use, misuse, or accidental swallowing of very high doses, central nervous system effects, including hallucinations or feelings of restlessness, have been reported. These effects are not associated with standard topical administration of the product.

Q: How long do initial side effects from Ginesal typically last?

Official regulatory documents state that any localized side effects, such as a temporary sensation of numbness or stinging at the application site, are typically transient. These feelings usually last only for a few minutes after using the product.

Q: Are there any long-term side effects associated with Ginesal use?

Ginesal is generally intended for short-term use. Official product information states that continuous, uninterrupted treatment should typically not exceed seven days unless continued under a doctor's supervision. Prolonged use may be associated with the development of localized hypersensitivity, which is an allergic-type reaction at the application site.

Q: Can I drink alcohol while taking Ginesal?

Regulatory documents note that some liquid formulations of Ginesal contain ethanol (alcohol). Official guidance suggests that the concurrent consumption of alcoholic beverages may increase the risk of rare systemic side effects, such as drowsiness or dizziness.

Q: Are there any foods I should avoid while using Ginesal?

According to official product labeling, there are no documented restrictions on specific food interactions with Ginesal. However, general advisory information suggests avoiding foods that could cause localized irritation, such as very hot or spicy items, especially when treating mouth ulcers.

Q: Does Ginesal have a warning about driving or operating machinery?

Official regulatory labeling states that Ginesal has negligible influence on the ability to drive and use machines when used topically as directed. However, official information advises caution if rare systemic effects such as dizziness or drowsiness are experienced.

Q: How quickly can a person expect to feel the effects of Ginesal?

Since Ginesal is a localized treatment, the symptomatic relief it provides should usually begin quickly. Official product information states that you can expect to feel the initial effects within a few minutes after using the product.

Q: How long does Ginesal stay in your system after taking a dose?

Ginesal is primarily for topical use, meaning its absorption into the bloodstream is negligible, and its action is localized. In the rare case of systemic absorption, such as after accidental swallowing, the drug's elimination half-life is typically reported to be approximately 7 to 13 hours.

Q: What is the typical time frame for reaching the full effect of Ginesal?

Ginesal is intended for immediate, short-term symptomatic relief. The effects of a single dose last for a few hours, and the product is reapplied as needed for pain. The maximum duration of continuous use is generally limited to seven days for acute conditions.

Q: Do the official documents mention any effects of missing a dose of Ginesal?

Official instructions indicate that if a dose is missed, the product can be used as soon as it is remembered, followed by continuation of the usual dosing schedule as required for pain relief. Official guidance advises against taking a double dose to make up for a missed one.

Q: Is it normal to feel no effect during the first few days of taking Ginesal?

Ginesal is intended to provide swift symptomatic relief, and the effect should usually be noticeable within a few minutes of use. If your symptoms do not start to improve or if they worsen after seven days of treatment, official guidance suggests contacting a healthcare provider.

Q: Why is Ginesal only available with a prescription?

The legal status of Ginesal (Benzydamine) varies depending on the country or region. It is available on prescription only (POM) in some markets, and may be available over-the-counter (OTC) or only from a pharmacy in others, depending on local regulatory classification.

Q: Has Ginesal been approved in other countries besides [Country X]?

Studies and official information indicate that Ginesal (Benzydamine hydrochloride) is approved and regulated for use in multiple global regions. This includes countries governed by bodies such as the MHRA (UK), HPRA (Ireland), and regulatory agencies across the EU, Australia, and Canada.

Q: Is the medication Ginesal associated with dependency or addiction concerns?

Ginesal (Benzydamine) is generally not considered habit-forming when used at the recommended topical dose. Reports of misuse involving central nervous system effects have been documented in official sources, but these are not associated with standard topical administration.

Q: Is it normal to have [nonspecific feeling] after starting Ginesal?

It is common to experience temporary localized sensations such as numbness, burning, or stinging at the application site. These are often transient effects. Official guidance suggests contacting a healthcare provider if any persistent or unusual feelings occur after starting Ginesal.

Q: What is the meaning of the medical terms used to describe Ginesal in the package insert?

The official package insert uses several technical terms. For example, 'inflammation' refers to the swelling, redness, and pain in the affected tissue. Warning terms like 'anaphylaxis' or 'bronchospasm' refer to rare but serious allergic-type reactions that are potentially life-threatening.

How should Ginesal be stored and disposed of?

Storage Conditions and Disposal

The official regulatory documents for Ginesal (Benzydamine hydrochloride) mandate specific conditions to ensure its stability and safety.

Requirement Official Instruction
Temperature Store at a controlled temperature, typically not above 25 C or 30 C, as specified on the label.
Protection Keep the product in its original container and protected away from light and moisture.
Stability (In-use) Liquid formulations (e.g., mouthwash, spray) must be used within six months of opening the container.
Child Safety The medicine must be stored out of the sight and reach of children.
Disposal Disposal of unused or expired Ginesal must be in accordance with local regulations; do not dispose of the medicine in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ginesal found in:

A-Z Index: